Signs Of Long-Term Efficacy Boost UniQure’s Hem B Gene Therapy
Will Await Main Study’s One-Year Milestone Before Submission
Executive Summary
Unveiling its latest data, UniQure is tipped to avoid the knockback which affected BioMarin’s hemophilia A gene therapy, with a filing expected in the second half of 2021.
You may also be interested in...
UniQure Needs Longer-Term Data For Hemophilia B Gene Therapy EtranaDez
The FDA may want longer follow-up data for companies developing treatments for hemophilia A as well as hemophilia B.
Relief For UniQure Hemophilia Program Sends Ball To FTC’s Court
While anticipated, the removal of the hold on uniQure’s hemophilia B program removes significant overhang, as the focus shifts to an anticipated FTC antitrust clearance of its CSL Behring deal.
UniQure Expects To Resolve FDA Clinical Hold Within Three Months
The gene therapy EtranaDez for hemophilia B placed on clinical hold after a patient was diagnosed with liver cancer, but UniQure points to that patient’s extensive history of liver disease.